Roche shares surge as a double-shot win in I/O and hemophilia raises blockbuster expectations
Roche has scored a win with one of the key immuno/oncology trials of the year, posting significant top-line gains for progression-free survival and risk of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
